Sanofi and Regeneron report positive skin disease trial - Reuters

Reuters

Sanofi and Regeneron report positive skin disease trial Reuters PARIS French drugmaker Sanofi SA and U.S. partner Regeneron Pharmaceuticals Inc said a one-year, late-stage study of dupilumab, a monoclonal antibody designed for the treatment of skin diseases, had met its main goals. "These are the first long-term ... Sanofi, Regeneron: Phase 3 Trial for Dupilumab Show Positive ResultsNasdaq Regeneron: Dupilumab With Topical Corticosteroids Superior To Treatment With TCSRTT News Stock is down at $400.75 (REGN) Regeneron and Sanofi Announce that...Finance Daily PR Newswire (press release) all 5 news articles »

from Health - Google News http://news.google.com/news/url?sa=t&fd=R&ct2=us&usg=AFQjCNEuwAGLN7-kvYC6nFtCBVn9-KP3eg&clid=c3a7d30bb8a4878e06b80cf16b898331&cid=52779127978300&ei=sRVVV5DLAZaI3AGl1JK4Ag&url=http://www.reuters.com/article/us-sanofi-regeneron-study-idUSKCN0YS0D9
via IFTTT